While we cannot assume these changes will be universal in all PDAC samples, this consistency suggests that some of these genes could make promising targets or biomarkers for APE1‐based therapy or combination therapies that potentially will be useful across multiple PDAC tumor subtypes and in other tumor types. The gene discussed is APEX1; the disease is neoplasm.